Pemetrexed and gemcitabine as combination therapy for the treatment of group3 medulloblastoma

Cancer Cell

Volumn 25, Issue 4, 2014, Pages 516-529

  Morfouace, Marie ^a   Shelat, Anang ^a   Jacus, Megan ^a   Freeman, Burgess B ^a   Turner, David ^a   Robinson, Sarah ^a   Zindy, Frederique ^a   Wang, Yong Dong ^a   Finkelstein, David ^a   Ayrault, Olivier ^b   Bihannic, Laure ^b   Puget, Stephanie ^c   Li, Xiao Nan ^d   Olson, James M ^e   Robinson, Giles W ^a   Guy, R Kiplin ^a   Stewart, Clinton F ^a   Gajjar, Amar ^a   Roussel, Martine F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b INSERM U1005   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; MYC PROTEIN; PEMETREXED; SONIC HEDGEHOG PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

ERINACEIDAE; MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; DEOXYCYTIDINE; GLUTAMATES; GUANINE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; PROGNOSIS;

EID: 84898544227     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.009     Document Type: Article

References (45)

1. Adjei A.A. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Semin. Oncol. 2002, 29(6, Suppl 18):30-34.
2. Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res. 2004, 10:4276s-4280s.
3. Atkinson J.M., Shelat A.A., Carcaboso A.M., Kranenburg T.A., Arnold L.A., Boulos N., Wright K., Johnson R.A., Poppleton H., Mohankumar K.M., et al. An integrated invitro and invivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011, 20:384-399.
4. Bailon O., Chouahnia K., Augier A., Bouillet T., Billot S., Coman I., Ursu R., Belin C., Zelek L., Des Guetz G., et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro-oncol. 2012, 14:491-495.
5. Chabot G.G., Rivard G.E., Momparler R.L. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res. 1983, 43:592-597.
6. Chattopadhyay S., Moran R.G., Goldman I.D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol. Cancer Ther. 2007, 6:404-417.
7. Dowell J.E., Dunphy F.R., Taub R.N., Gerber D.E., Ngov L., Yan J., Xie Y., Kindler H.L. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012, 77:567-571.
8. Dubuc A.M., Remke M., Korshunov A., Northcott P.A., Zhan S.H., Mendez-Lago M., Kool M., Jones D.T., Unterberger A., Morrissy A.S., et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2013, 125:373-384.
9. Ellison D.W., Kocak M., Dalton J., Megahed H., Lusher M.E., Ryan S.L., Zhao W., Nicholson S.L., Taylor R.E., Bailey S., Clifford S.C. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J.Clin. Oncol. 2011, 29:1400-1407.
10. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 2007, 6:1239-1248.
11. George R.E., Lahti J.M., Adamson P.C., Zhu K., Finkelstein D., Ingle A.M., Reid J.M., Krailo M., Neuberg D., Blaney S.M., Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2010, 55:629-638.
12. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., Finkelstein D., Qu C., Pounds S., Ellison D.W., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012, 21:168-180.
13. Kerr J.Z., Berg S.L., Dauser R., Nuchtern J., Egorin M.J., McGuffey L., Aleksic A., Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother. Pharmacol. 2001, 47:411-414.
14. Kool M., Korshunov A., Remke M., Jones D.T., Schlanstein M., Northcott P.A., Cho Y.J., Koster J., Schouten-van Meeteren A., van Vuurden D., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123:473-484.
15. Kumthekar P., Grimm S.A., Avram M.J., Kaklamani V., Helenowski I., Rademaker A., Cianfrocca M., Gradishar W., Patel J., Mulcahy M., et al. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J.Neurooncol. 2013, 112:247-255.
16. Ma C.X., Nair S., Thomas S., Mandrekar S.J., Nikcevich D.A., Rowland K.M., Fitch T.R., Windschitl H.E., Hillman S.L., Schild S.E., et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J.Clin. Oncol. 2005, 23:5929-5937. North Central Cancer Treatment Group, Mayo ClinicMayo Clinic, Eli Lilly & CompanyEli Lilly & Company.
17. Malempati S., Nicholson H.S., Reid J.M., Blaney S.M., Ingle A.M., Krailo M., Stork L.C., Melemed A.S., McGovern R., Safgren S., et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J.Clin. Oncol. 2007, 25:1505-1511. Children's Oncology Group.
18. Massimino M., Cefalo G., Riva D., Biassoni V., Spreafico F., Pecori E., Poggi G., Collini P., Pollo B., Valentini L., et al. Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. J.Neurooncol. 2012, 108:163-171.
19. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
20. Monnerat C., Le Chevalier T. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann. Oncol. 2006, 17(Suppl 5):v86-v90.
21. Mubarak N., Gaafar R., Shehata S., Hashem T., Abigeres D., Azim H.A., El-Husseiny G., Al-Husaini H., Liu Z. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer 2012, 12:423.
22. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., et al. Medulloblastoma comprises four distinct molecular variants. J.Clin. Oncol. 2011, 29:1408-1414.
23. Northcott P.A., Korshunov A., Pfister S.M., Taylor M.D. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012, 8:340-351.
24. Packer R.J., Zhou T., Holmes E., Vezina G., Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro. Oncol. 2013, 15:97-103.
25. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 2008, 28:752-771.
26. Parsons D.W., Li M., Zhang X., Jones S., Leary R.J., Lin J.C., Boca S.M., Carter H., Samayoa J., Bettegowda C., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
27. Pugh T.J., Weeraratne S.D., Archer T.C., Pomeranz Krummel D.A., Auclair D., Bochicchio J., Carneiro M.O., Carter S.L., Cibulskis K., Erlich R.L., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488:106-110.
28. Rausch T., Jones D.T., Zapatka M., Stütz A.M., Zichner T., Weischenfeldt J., Jäger N., Remke M., Shih D., Northcott P.A., et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012, 148:59-71.
29. Reid J.M., Qu W., Safgren S.L., Ames M.M., Krailo M.D., Seibel N.L., Kuttesch J., Holcenberg J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J.Clin. Oncol. 2004, 22:2445-2451.
30. Robinson G., Parker M., Kranenburg T.A., Lu C., Chen X., Ding L., Phoenix T.N., Hedlund E., Wei L., Zhu X., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012, 488:43-48.
31. Rocchetti M., Simeoni M., Pesenti E., De Nicolao G., Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur. J. Cancer 2007, 43:1862-1868.
32. Saggar J.K., Fung A.S., Patel K.J., Tannock I.F. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol. Cancer Ther. 2013, 12:542-552.
33. Shu Q., Wong K.K., Su J.M., Adesina A.M., Yu L.T., Tsang Y.T., Antalffy B.C., Baxter P., Perlaky L., Yang J., et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 2008, 26:1414-1424.
34. Stapleton S.L., Reid J.M., Thompson P.A., Ames M.M., McGovern R.M., McGuffey L., Nuchtern J., Dauser R., Blaney S.M. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother. Pharmacol. 2007, 59:461-466.
35. Taylor M.D., Northcott P.A., Korshunov A., Remke M., Cho Y.J., Clifford S.C., Eberhart C.G., Parsons D.W., Rutkowski S., Gajjar A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012, 123:465-472.
36. Tonkinson J.L., Worzalla J.F., Teng C.H., Mendelsohn L.G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999, 59:3671-3676.
37. Uziel T., Zindy F., Xie S., Lee Y., Forget A., Magdaleno S., Rehg J.E., Calabrese C., Solecki D., Eberhart C.G., et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005, 19:2656-2667.
38. van Moorsel C.J., Bergman A.M., Veerman G., Voorn D.A., Ruiz van Haperen V.W., Kroep J.R., Pinedo H.M., Peters G.J. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim. Biophys. Acta 2000, 1474:5-12.
39. Wang H., Li M., Rinehart J.J., Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: invivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res. 2004, 10:1633-1644.
40. Warwick A.B., Malempati S., Krailo M., Melemed A., Gorlick R., Ames M.M., Safgren S.L., Adamson P.C., Blaney S.M. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2013, 60:237-241.
41. Wetmore C., Eberhart D.E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001, 61:513-516.
42. White L., Sterling-Levis K. Multiagent chemotherapy studied in axenograft model of medulloblastoma/primitive neuroectodermal tumour: analysis of the VETOPEC regimen. J.Clin. Neurosci. 2008, 15:49-54.
43. Woodland J.M., Barnett C.J., Dorman D.E., Gruber J.M., Shih C., Spangle L.A., Wilson T.M., Ehlhardt W.J. Metabolism and disposition of the antifolate LY231514 in mice and dogs. Drug Metab. Dispos. 1997, 25:693-700.
44. Zhao X., Liu Z., Yu L., Zhang Y., Baxter P., Voicu H., Gurusiddappa S., Luan J., Su J.M., Leung H.C., Li X.N. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-oncol. 2012, 14:574-583.
45. Zhuang Y., Fraga C.H., Hubbard K.E., Hagedorn N., Panetta J.C., Waters C.M., Stewart C.F. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res. 2006, 66:11305-11313.